Brandon is a drug developer with deep oncology and immunology experience. He has a particular focus on how CROs can support in expanding the capabilities of small biotech companies. In his current role, he oversees and develops high performance teams to deliver client clinical development portfolios. Prior to his time with ICON, Brandon led global oncology and immuno-oncology programmes in the biotech and CRO sectors. He received his Masters and Undergraduate degrees from the University of Virginia, US.